Dr Daniel Billen

Dr Daniel Billen has been appointed chair of the recently created Ontario Bioscience Economic Strategy Team (OBEST) advisory committee. Billen is GM Amgen Canada and was chosen to head up an initiative to develop an evergreen strategy for sustaining the province's health sciences industry. An initiative of the Ontario Bioscience Industry Organization (OBIO) — a council of chief executive officers of Ontario-based bioscience companies financially supported by the provincial government — the 16-member OBEST committee will consult widely and focus on the convergence of industry, academia, government, patients, capital markets, and health, finance, research and innovation in government. The strategy will be constantly revisited and revised as OBEST conducts its consultations….